Gene therapy, CRISPR, synthetic biology, and emerging platforms—what's real, what's hype, and what translates.
Emerging evidence suggests that ultra-low doses of costly cancer immunotherapies may dramatically increase treatment accessibility in poorer nations without compromising efficacy.
Emerging evidence suggests that ultra-low doses of costly cancer immunotherapies may dramatically increase treatment accessibility in poorer nations without compromising efficacy.
READ MORE
Recent findings presented at ASCO 2026 reveal that daraxonrasib, a novel drug targeting pancreatic cancer, effectively inhibits a challenging molecular target, offering new hope for treatment of this aggressive disease.
AbbVie's antibody-drug conjugate Decnupaz has received FDA approval for treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer.
Eli Lilly’s novel gene-editing therapy demonstrated a significant 62% reduction in cholesterol levels in a Phase 1 clinical trial, marking a potential breakthrough in cardiovascular disease management.
Germany is positioning itself as a leading biotech hub in Europe, fueled by robust infrastructure, scientific excellence, and evolving policies aimed at scaling life science companies globally.
Eli Lilly has acquired Engage Bio, a startup pioneering a non-viral DNA delivery platform, expanding its strategic capabilities in the development of genetic medicines.
A UCSF team is on the verge of launching a groundbreaking clinical trial testing gene therapy administered before birth to treat a rare lysosomal storage disorder.
The biotechnology sector is facing unprecedented challenges as it operates under the financial, governance, and regulatory frameworks designed for mature pharmaceutical companies rather than discovery-oriented innovation entities.
Duracyte introduces a novel approach to biologic drug manufacturing through implantable cell factories that produce therapeutic proteins inside the body, monitored by integrated sensors.
BeOne’s Beqalzi has received FDA approval as the first BCL2 inhibitor approved for relapsed or refractory mantle cell lymphoma, marking a significant advance in therapy options.
Isomorphic Labs has raised $2.1 billion, marking the second largest funding round ever for a biotech company, despite not yet having disclosed a molecule or reached clinical trials.
